Merck Group

merckgroup.com

Not intended for US & CA visitors. At the biopharma business of Merck, we have an enduring commitment and focus in our specialist therapeutic areas of oncology, neurodegenerative diseases, fertility and endocrinology, along with rheumatology as an emerging area of expertise. We also provide a portfolio of cardiometabolic care and general medicine products, especially in emerging markets where patient need remains high.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RESEARCH

NANOFORM RELEASES NEXT-GENERATION AI-BASED DRUG SELECTION TOOL

Nanoform | March 23, 2021

news image

Nanoform innovative nanoparticle medicine enabling company next generation of its STARMAP® AI artificial intelligence platform nanoparticle bioavailability excipient microns nm CESS technology silico pharma drugs lifecycle managementNanoform, an innovative nanoparticle medicine enabling company, has today dispatched the next generation of its STARMAP® AI (artificial intelligence) platform, v2.0. The technology uses scanty information AI to expand trial results from its CESS® nanopart...

Read More

PHARMACY MARKET

KEDALION THERAPEUTICS SECURES SERIES B FUNDING AND ANNOUNCES SIGNING OF OPTION TO ACQUIRE AGREEMENT

Kedalion Therapeutics, | November 16, 2021

news image

Kedalion Therapeutics is pleased to announce the completion of its Series B financing led by Novartis and involving a combination of new and existing investors. The Novartis investment includes an Exclusive Option to Acquire the company and its AcuStream™ technology. This agreement follows a Feasibility Study agreement with the AcuStream™ technology signed earlier this year. The subsequent feasibility study has been completed with successful results. Collaboration between the t...

Read More

TACKLING THE INNOVATION CRISIS IN DRUG DISCOVERY AND DEVELOPMENT

Technology Networks | February 17, 2020

news image

Arctoris Ltd has announced a formal partnership with Molecule in order to tackle the ongoing innovation crisis faced by drug discovery and development across both industry and academia. Through its fully automated drug discovery platform, Arctoris aims to enable researchers and biotechnological entrepreneurs to design and remotely execute advanced cell-based, molecular biology and biochemical assays. Together with Molecule’s distributed IP ownership platform, which enables stakeholders in ...

Read More

GILEAD RESCINDS ORPHAN STATUS REQUEST FOR COVID-19 DRUG

pharma news | March 26, 2020

news image

Gilead has rescinded its request for orphan status for its potential COVID-19 antiviral remdesivir amid a furore over its pricing should it get to market. By asking for orphan status the US pharma sparked concerns that it would charge a premium price for remdesivir, which is being trialled against the disease. Remdesivir has been described by the World Health Organisation as the best hope for a therapy, at least until a vaccine is developed. Gilead decided to rescind the request for orphan statu...

Read More
news image

RESEARCH

NANOFORM RELEASES NEXT-GENERATION AI-BASED DRUG SELECTION TOOL

Nanoform | March 23, 2021

Nanoform innovative nanoparticle medicine enabling company next generation of its STARMAP® AI artificial intelligence platform nanoparticle bioavailability excipient microns nm CESS technology silico pharma drugs lifecycle managementNanoform, an innovative nanoparticle medicine enabling company, has today dispatched the next generation of its STARMAP® AI (artificial intelligence) platform, v2.0. The technology uses scanty information AI to expand trial results from its CESS® nanopart...

Read More
news image

PHARMACY MARKET

KEDALION THERAPEUTICS SECURES SERIES B FUNDING AND ANNOUNCES SIGNING OF OPTION TO ACQUIRE AGREEMENT

Kedalion Therapeutics, | November 16, 2021

Kedalion Therapeutics is pleased to announce the completion of its Series B financing led by Novartis and involving a combination of new and existing investors. The Novartis investment includes an Exclusive Option to Acquire the company and its AcuStream™ technology. This agreement follows a Feasibility Study agreement with the AcuStream™ technology signed earlier this year. The subsequent feasibility study has been completed with successful results. Collaboration between the t...

Read More
news image

TACKLING THE INNOVATION CRISIS IN DRUG DISCOVERY AND DEVELOPMENT

Technology Networks | February 17, 2020

Arctoris Ltd has announced a formal partnership with Molecule in order to tackle the ongoing innovation crisis faced by drug discovery and development across both industry and academia. Through its fully automated drug discovery platform, Arctoris aims to enable researchers and biotechnological entrepreneurs to design and remotely execute advanced cell-based, molecular biology and biochemical assays. Together with Molecule’s distributed IP ownership platform, which enables stakeholders in ...

Read More
news image

GILEAD RESCINDS ORPHAN STATUS REQUEST FOR COVID-19 DRUG

pharma news | March 26, 2020

Gilead has rescinded its request for orphan status for its potential COVID-19 antiviral remdesivir amid a furore over its pricing should it get to market. By asking for orphan status the US pharma sparked concerns that it would charge a premium price for remdesivir, which is being trialled against the disease. Remdesivir has been described by the World Health Organisation as the best hope for a therapy, at least until a vaccine is developed. Gilead decided to rescind the request for orphan statu...

Read More